This Article Full Text Full Text (PDF) Supplemental material Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fu, Q. Articles by O'Brien, C. A. Search for Related Content PubMed PubMed Citation Articles by Fu, Q. Articles by O'Brien, C. A.

Parathyroid Hormone Controls Receptor Activator of NF-B Ligand Gene Expression via a Distant Transcriptional Enhancer

Division of Endocrinology & Metabolism, Department of Medicine, Center for Osteoporosis & Metabolic Bone Diseases, University of Arkansas for Medical Sciences, and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, 72205

Received 27 February 2006/ Returned for modification 5 May 2006/ Accepted 12 June 2006

RANKL, a protein essential for osteoclast development and survival, is stimulated by parathyroid hormone (PTH) via a PTH receptor 1/cyclic AMP (cAMP)/protein kinase A (PKA)/CREB cascade, exclusively in osteoblastic cells. We report that a bacterial artificial chromosome-based transcriptional reporter construct containing 120 kb of RANKL 5'-flanking region was stimulated by dibutyryl-cAMP in stromal/osteoblastic cells, but not other cell types. Full cAMP responsiveness was dependent upon a conserved 715-bp region located 76 kb upstream from the transcription start site, which we identified by sequential deletion analysis and by comparison of human and mouse genomic sequences in silico. This region contained conserved consensus sequences which bound CREB and the osteoblast-specific transcription factor Runx2, and when mutated blunted cAMP responsiveness. Overexpression of Runx2 potentiated cAMP responsiveness of the endogenous RANKL gene in a cell-type-specific manner. Lastly, PTH responsiveness of the endogenous RANKL gene was abrogated in mice from which we deleted this conserved upstream region. Thus, PTH responsiveness of the RANKL gene is determined by a distant regulatory region that responds to cAMP in a cell-type-specific manner and Runx2 may contribute to such cell-type specificity.

Supplemental material for this article may be found at http://mcb.asm.org/.

This article has been cited by other articles:

• Nerenz, R. D., Martowicz, M. L., Pike, J. W. (2008). An Enhancer 20 Kilobases Upstream of the Human Receptor Activator of Nuclear Factor-{kappa}B Ligand Gene Mediates Dominant Activation by 1,25-Dihydroxyvitamin D3. Mol. Endocrinol. 22: 1044-1056 [Abstract] [Full Text]  
• Galli, C., Zella, L. A., Fretz, J. A., Fu, Q., Pike, J. W., Weinstein, R. S., Manolagas, S. C., O'Brien, C. A. (2008). Targeted Deletion of a Distant Transcriptional Enhancer of the Receptor Activator of Nuclear Factor-{kappa}B Ligand Gene Reduces Bone Remodeling and Increases Bone Mass. Endocrinology 149: 146-153 [Abstract] [Full Text]  
• Ono, N., Nakashima, K., Schipani, E., Hayata, T., Ezura, Y., Soma, K., Kronenberg, H. M., Noda, M. (2007). Constitutively Active Parathyroid Hormone Receptor Signaling in Cells in Osteoblastic Lineage Suppresses Mechanical Unloading-induced Bone Resorption. J. Biol. Chem. 282: 25509-25516 [Abstract] [Full Text]  
• Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., Swain, F. L., Suva, L. J., Lecka-Czernik, B. (2007). Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone. Endocrinology 148: 2669-2680 [Abstract] [Full Text]  
• Kim, S., Yamazaki, M., Shevde, N. K., Pike, J. W. (2007). Transcriptional Control of Receptor Activator of Nuclear Factor-{kappa}B Ligand by the Protein Kinase A Activator Forskolin and the Transmembrane Glycoprotein 130-Activating Cytokine, Oncostatin M, Is Exerted through Multiple Distal Enhancers. Mol. Endocrinol. 21: 197-214 [Abstract] [Full Text]